The Khavinson school — how a St Petersburg research group established an entire peptide family

A tradition that grew parallel to the Western mainstream

In the 1970s, Vladimir Khavinson — then a young military physician with a research role at the Soviet Military Academy in Leningrad — began pursuing an unusual hypothesis: that age-related functional losses in various organ systems could be modulated by extracted oligopeptide complexes. The starting idea was simple: every organ type produces characteristic low-molecular peptide signals; this production declines with age; exogenous substitution should partially restore function.

From this idea, a whole substance family emerged over the 1980s and 1990s. It includes thymus extracts (thymalin, vilon), pineal extracts (epithalamin) and later synthetic simplifications — most prominently epitalon (Ala-Glu-Asp-Gly), a tetrapeptide postulated as the synthetic essence of the epithalamin complex. Khavinson and his co-authors published hundreds of papers in Russian journals over decades, with increasing presence in PubMed-listed publications from the 2000s.

The clinical apparatus

What distinguishes the Khavinson school from other peptide lines is its embedding in the Russian health system. Several of its preparations — thymalin, cortexin, retinalamin, prostatilen, epithalamin — are approved as prescription medicines in Russia and some CIS states. They are used clinically for infections, post-stroke sequelae, retinopathies and gynaecological indications. From the St Petersburg institute, several generations of clinically active researchers have emerged over the decades.

In parallel, the long-running geriatric observational studies central to the anti-aging claims of the Khavinson line continue. The best known — St Petersburg cohorts from the 1980s onwards — report extensions of mean life expectancy of 25-40% in treated elderly patients compared with controls. These figures have appeared repeatedly in Russian publications, both for thymalin and for epithalamin.

Why Western science remains sceptical

From a Western methodological perspective, four central weaknesses exist. First: practically all positive findings come from the Khavinson institute or closely cooperating groups. Independent Western replication does not exist for most substances. Second: the methodological standards of the reported clinical studies often do not meet ICH-GCP requirements (no blinding against active comparator, small samples, selection and endpoint definitions not Western-compliant). Third: the postulated mechanisms of action — from the 2000s, Khavinson proposed that short peptides interact directly with DNA and act gene-regulatory — are not molecular-biologically validated in the Western mainstream. Fourth: the multi-component preparations (thymalin, cortexin) are not standardised like a synthetic single peptide — batch-to-batch variability is cited in Western reviews as a systematic problem.

This does not mean the Russian findings are false. It means the evidence base is methodologically limited and, outside the original research ecosystem, not in a form Western regulatory authorities would consider sufficient.

International adoption as an anti-aging phenomenon

From the 2010s, epitalon, thymalin and cortexin were increasingly discussed in English-language longevity and bio-hacking communities. Various wellness/longevity podcasts, individual high-reach interviews and Twitter threads contributed to their spread. The substances became available through Russian pharmacy imports and research-chemical vendors — often without clean identity or purity control.

This diffusion has placed the Khavinson substances in a peculiar position: in Russia, approved medicines with long-standing clinical tradition; in the West, unapproved and largely traded as 'research chemicals'; in the anti-aging subculture, treated as an insider tip. Three different realities of the same substance.

What the Khavinson story methodologically shows

The Khavinson line is a teaching case of a rarely discussed phenomenon: a scientific tradition can be productive for decades and build a clinical apparatus around itself without its central claims being methodologically cleanly replicated outside its own ecosystem. This is neither pseudoscience in the classical sense — the studies are real, the patients are real, the reported effects are internally consistent within their own methodology — nor is it established evidence in the international sense.

For assessing individual substances from this corpus, this means: 'approved in Russia' is a fact with clinical significance in its jurisdiction, but not an automatic quality signal by Western standards. 'Effect in Khavinson study' is a fact with internal consistency, but not an externally replicated active profile. Both statements are true — simultaneously.

Open questions

• Which Khavinson substances would be most sensible for ICH-GCP-compliant replication studies — and who would fund them?
• Can the postulated gene-regulatory mechanisms of short peptides be tested with modern molecular-biological methods (proteomics, ChIP-Seq)?
• How should authorities in the EU and US handle imports from Russia — as unapproved medicines, as research substances, or as foodstuffs?
• How do geopolitical tensions from 2022 affect scientific exchange and replication possibilities?